Artivion (NYSE:AORT) Price Target Raised to $30.00

Artivion (NYSE:AORT) had its target price upped by Stifel Nicolaus from $28.00 to $30.00 in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on AORT. Needham & Company LLC reiterated a buy rating and set a $30.00 price target on shares of Artivion in a research note on Friday, August 9th. Lake Street Capital lifted their target price on shares of Artivion from $28.00 to $30.00 and gave the company a buy rating in a research report on Tuesday, July 2nd. Finally, Oppenheimer increased their price target on shares of Artivion from $25.00 to $30.00 and gave the stock an outperform rating in a research report on Friday, August 9th.

Artivion Stock Performance

NYSE AORT opened at $25.25 on Friday. The company’s fifty day moving average is $26.14 and its two-hundred day moving average is $23.49. Artivion has a 52-week low of $12.16 and a 52-week high of $29.24. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.63 and a quick ratio of 4.04. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -105.21 and a beta of 1.74.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.04. The firm had revenue of $98.02 million for the quarter, compared to analyst estimates of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. Equities research analysts forecast that Artivion will post 0.2 EPS for the current year.

Insider Transactions at Artivion

In other Artivion news, SVP Jean F. Holloway sold 3,167 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $26.55, for a total transaction of $84,083.85. Following the sale, the senior vice president now directly owns 161,932 shares of the company’s stock, valued at $4,299,294.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, SVP Jean F. Holloway sold 2,383 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $25.76, for a total value of $61,386.08. Following the completion of the sale, the senior vice president now directly owns 165,099 shares in the company, valued at $4,252,950.24. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Jean F. Holloway sold 3,167 shares of Artivion stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $26.55, for a total value of $84,083.85. Following the completion of the transaction, the senior vice president now directly owns 161,932 shares of the company’s stock, valued at $4,299,294.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,679 shares of company stock valued at $626,518. 8.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Artivion

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in shares of Artivion in the 2nd quarter valued at $28,000. GAMMA Investing LLC boosted its holdings in Artivion by 38.6% in the first quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock valued at $38,000 after acquiring an additional 505 shares during the last quarter. RiverPark Advisors LLC acquired a new stake in Artivion in the second quarter worth about $55,000. Register Financial Advisors LLC acquired a new stake in Artivion in the first quarter worth about $114,000. Finally, Allspring Global Investments Holdings LLC raised its holdings in Artivion by 291.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock worth $118,000 after purchasing an additional 4,154 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.